Role of preoperative platelet level in clinical and pathological outcomes after surgery for renal cortical malignancies

BJU International

Volumn 108, Issue 1, 2011, Pages 73-79

  Wosnitzer, Matthew ^a   Polland, Allison ^a   Hai, Qiong ^b   Hruby, Gregory ^a   McKiernan, James ^a  

^a Department of Urology ^*  (United States)

^b Department of Medicine   (United States)

Author keywords

partial nephrectomy; preoperative platelet count; radical nephrectomy; recurrence; renal cell carcinoma; thrombocytosis

Indexed keywords

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; THROMBOCYTE COUNT; THROMBOCYTOSIS; TUMOR VOLUME;

CARCINOMA, RENAL CELL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; KIDNEY CORTEX; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEPHRECTOMY; PLATELET COUNT; PREOPERATIVE PERIOD; PROGNOSIS; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 79959314176     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09889.x     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al,. Cancer statistics. CA Cancer J Clin 2009; 59: 225-49
2. Zisman A, Pantuck AJ, Wieder J, et al,. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 4559-66 (Pubitemid 35402959)
3. Frank I, Blute ML, Cheville JC, et al,. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395-400 (Pubitemid 35402623)
4. Kattan MW, Reuter V, Motzer RJ, et al,. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166: 63-7 (Pubitemid 32565343)
5. McMillan DC, Elahi MM, Sattar N, et al. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001; 41: 64-9 (Pubitemid 34666222)
6. Crumley AB, McMillan DC, McKernan M, et al,. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 2006; 94: 637-41 (Pubitemid 43361893)
7. Forrest LM, McMillan DC, McArdle CS, et al,. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003; 89: 1028-30 (Pubitemid 37239206)
8. Glen P, Jamieson NB, McMillan DC, et al,. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006; 6: 450-3 (Pubitemid 44624278)
9. Gogus C, Baltaci S, Filiz E, et al,. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 2004; 63: 447-50
10. Inoue K, Kohashikawa K, Suzuki S, et al,. Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol 2004; 11: 364-7 (Pubitemid 38858931)
11. O'Keefe SC, Marshall FF, Issa MM, et al,. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 2002; 168: 1378-80 (Pubitemid 35034126)
12. Levin J, Conley CL,. Thrombocytosis associated with malignant disease. Arch Intern Med 1964; 114: 497-500
13. Nieswandt B, Hafner M, Echtenacher B, et al,. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-30
14. Kim YJ, Borsig L, Varki NM, et al,. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 1998; 95: 9325-30 (Pubitemid 28506230)
15. Hernandez E, Lavine M, Dunton CJ, et al,. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992; 69: 2975-7
16. Ikeda M, Furukawa H, Imamura H, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-91 (Pubitemid 34298634)
17. Arbiser JL, Moses MA, Fernandez CA, et al,. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997; 94: 861-6 (Pubitemid 27074412)
18. Gnarra JR, Zhou S, Merrill MJ, et al,. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996; 93: 10589-94 (Pubitemid 26333031)
19. Linehan WM, Walther MM, Zbar B,. The genetic basis of cancer of the kidney. J Urol 2003; 170: 2163-72 (Pubitemid 37413950)
20. Senger DR, Galli SJ, Dvorak AM, et al,. tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5
21. Takahashi K, Mulliken JB, Kozakewich HP, et al,. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93: 2357-64 (Pubitemid 24177146)
22. Ito K, Asano T, Yoshii H, et al,. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 2006; 13: 1365-70 (Pubitemid 44657040)
23. Bromwich EJ, McArdle PA, Canna K, et al,. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003; 89: 1906-8 (Pubitemid 37533268)
24. Ramsey S, Lamb GW, Aitchison M, et al,. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 2008; 101: 959-63 (Pubitemid 351422556)
25. Salgado R, Vermeulen PB, Benoy I, et al,. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80: 892-7 (Pubitemid 29209856)
26. Bensalah K, Leray E, Fergelot P, et al,. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006; 175: 859-63 (Pubitemid 43199997)
27. Suppiah R, Shaheen PE, Elson P, et al,. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006; 107: 1793-800 (Pubitemid 44582948)
28. Symbas NP, Townsend MF, El-Galley R, et al,. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86: 203-7 (Pubitemid 30621216)
29. Erdemir F, Kilciler M, Bedir S, et al,. Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 2007; 79: 111-6 (Pubitemid 47402734)
30. Lee SE, Byun SS, Han JH, et al,. Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int 2006; 98: 1228-32 (Pubitemid 44721231)
31. Choueiri TK, Plantade A, Elson P, et al,. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-31
32. Heng DY, Xie W, Regan MM, et al,. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9